Aquestive Therapeutics (AQST) reported Q4 net loss Wednesday of $0.19 per share, widening from a loss of $0.12 a year earlier.
Two analysts polled by FactSet expected a loss of $0.14.
Revenue for the quarter ended Dec. 31 was $11.9 million, down from $13.2 million a year earlier.
Analysts surveyed by FactSet expected $13.1 million.
For the full-year 2025, the company said it expects total revenue in the range of $47 million to $56 million. Analysts polled by FactSet expect $53 million.
Aquestive's stock was down 4.3% in after-hours activity Wednesday.
Price: 2.67, Change: -0.12, Percent Change: -4.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.